Literature DB >> 8725045

Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation.

I Sasagawa1, T Nakada, Y Kubota, T Sawamura, K Izumiya.   

Abstract

Eighteen previously untreated patients with metastatic carcinoma of the prostate were treated with LHRH analogue. They were divided into 3 groups according to the degree of glandular differentiation. In all groups, a transient rise of PAP and PSA was observed after the LH and testosterone surge. However, relative values of LH, testosterone, PAP and PSA did not differ significantly among the 3 groups. These facts suggest that a transient rise of PAP and PSA is caused by testosterone surge independently from the degree of glandular differentiation after LHRH analogue administration in patients with advanced prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8725045     DOI: 10.1007/BF02552145

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  15 in total

Review 1.  What is new in endocrine therapy of prostatic cancer?

Authors:  F H Schröder
Journal:  Prog Clin Biol Res       Date:  1990

2.  Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.

Authors:  A V Kaisary; C J Tyrrell; W B Peeling; K Griffiths
Journal:  Br J Urol       Date:  1991-05

Review 3.  Prostatic complications of testosterone replacement therapy.

Authors:  J A Jackson; J Waxman; A M Spiekerman
Journal:  Arch Intern Med       Date:  1989-10

4.  Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.

Authors:  J A Smith
Journal:  J Urol       Date:  1984-06       Impact factor: 7.450

5.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  Multiple marker evaluation in prostatic cancer using prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase.

Authors:  Y Arai; T Yoshiki; K Okada; O Yoshida
Journal:  Urol Int       Date:  1989       Impact factor: 2.089

7.  A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.

Authors:  H Winfield; J Trachtenberg
Journal:  J Urol       Date:  1984-06       Impact factor: 7.450

8.  Newer methods of hormonal therapy for prostate cancer.

Authors:  M S Soloway
Journal:  Urology       Date:  1984-11       Impact factor: 2.649

9.  Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells.

Authors:  M F Lin; J DaVolio; R Garcia-Arenas
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

10.  Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.

Authors:  N Faure; F Labrie; A Lemay; A Bélanger; Y Gourdeau; B Laroche; G Robert
Journal:  Fertil Steril       Date:  1982-03       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.